New York and Toronto Norton Rose Fulbright team advises Telesta on exclusive licensing agreement with Ipsen

Business October 30, 2015

A Norton Rose Fulbright life sciences transactions team recently advised longtime client Telesta Therapeutics (TSX:TST; PNK:BNHLF) on an exclusive licensing agreement with Ipsen (Euronext: IPN - ADR: IPSEY).
In the transaction, Telesta and Ipsen entered into an exclusive licensing agreement for Ipsen to develop and commercialize MCNA for the treatment of high risk non-muscle invasive bladder cancer (NMIBC) in all countries of the world, with the exception of the United States, where Telesta is establishing commercial operations, Canada, South Africa, Mexico, South Korea and Japan.
Telesta is eligible to receive up to US$137 million in upfront and milestone payments comprising a US$10 million upfront payment and additional payments contingent upon achievement of regulatory and sales milestones. In addition, Telesta is eligible to receive meaningful tiered double-digit royalties on net sales of MCNA in the licensed territories.

Telesta retains full and sole ownership of MCNA rights in the US and Japan and will be responsible for the commercial launch of MCNA in the United States while Ipsen will immediately initiate discussions with regulatory authorities to identify the regulatory path and potential requirements for the product in Europe and other key licensed territories.

New York partner Andres Liivak led the Norton Rose Fulbright team on the matter, while Toronto associate Steven Zuccarelli provided support. Telesta has been a client of the firm for more than 20 years.

For further information please contact:

Elisabeth Besson, senior public relations advisor
Tel: +1 514 847 4349; Mob: +1 514 688 0876
elisabeth.besson@nortonrosefulbright.com

About Norton Rose Fulbright

Norton Rose Fulbright is a global law firm. We provide the world’s preeminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.


For more information about Norton Rose Fulbright, see nortonrosefulbright.com/legal-notices.

Law around the world
nortonrosefulbright.com